Paul Bieniasz to Antibodies, Monoclonal
This is a "connection" page, showing publications Paul Bieniasz has written about Antibodies, Monoclonal.
Connection Strength
0.223
-
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020 11 02; 217(11).
Score: 0.055
-
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020 10 28; 9.
Score: 0.055
-
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 2021 07 07; 12(1):4196.
Score: 0.014
-
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathog. 2021 07; 17(7):e1009688.
Score: 0.014
-
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 07; 595(7867):426-431.
Score: 0.014
-
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell. 2021 06 10; 184(12):3205-3221.e24.
Score: 0.014
-
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021 05; 593(7859):424-428.
Score: 0.014
-
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 04; 592(7855):616-622.
Score: 0.014
-
Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 03; 591(7851):639-644.
Score: 0.014
-
Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 08; 584(7821):437-442.
Score: 0.013